Sorrento Therapeutics, Inc. (SRNE): Price and Financial Metrics


Sorrento Therapeutics, Inc. (SRNE)

Today's Latest Price: $8.22 USD

0.67 (-7.54%)

Updated Oct 20 4:00pm

Add SRNE to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

SRNE Stock Summary

  • With a price/sales ratio of 60.54, Sorrento Therapeutics Inc has a higher such ratio than 96.32% of stocks in our set.
  • With a year-over-year growth in debt of -28.83%, Sorrento Therapeutics Inc's debt growth rate surpasses merely 9.96% of about US stocks.
  • In terms of volatility of its share price, SRNE is more volatile than 96.07% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sorrento Therapeutics Inc are VERU, RTRX, KPTI, VECO, and ATNX.
  • SRNE's SEC filings can be seen here. And to visit Sorrento Therapeutics Inc's official web site, go to www.sorrentotherapeutics.com.

SRNE Stock Price Chart Interactive Chart >

Price chart for SRNE

SRNE Price/Volume Stats

Current price $8.22 52-week high $19.39
Prev. close $8.89 52-week low $1.45
Day low $8.10 Volume 17,912,700
Day high $8.92 Avg. volume 26,863,979
50-day MA $9.63 Dividend yield N/A
200-day MA $5.71 Market Cap 2.15B

Sorrento Therapeutics, Inc. (SRNE) Company Bio


Sorrento Therapeutics is a clinical stage oncology company developing new treatments for cancer and associated pain. The company was founded in 2006 and is based in San Diego, California.


SRNE Latest News Stream


Event/Time News Detail
Loading, please wait...

SRNE Latest Social Stream


Loading social stream, please wait...

View Full SRNE Social Stream

Latest SRNE News From Around the Web

Below are the latest news stories about Sorrento Therapeutics Inc that investors may wish to consider to help them evaluate SRNE as an investment opportunity.

Sorrento anti-SARS-CoV-2 antibodies show encouraging action in preclinical studies

Sorrento Therapeutics (SRNE) shares up 6% in premarket, in reaction to preclinical data on COVI-GUARD (STI-1499) and COVI-AMG (STI-2020) antibodies against SARS-CoV-2, and both demonstrated neutralizing activities against SARS-CoV-2 virus infection.In May, it announced that STI-1499 completely inhibited SARS-CoV-2 infection in an in vitro experiment at low concentrationSTI-2020 is an affinity-matured version of the...

Seeking Alpha | September 29, 2020

Sorrento Identifies Second 'More Potent' Anti-COVID-19 Antibody For Clinical Testing

Sorrento Therapeutics Inc (NASDAQ: SRNE ) shares are rising again following gains in the previous two sessions. What Happened: San Diego, California-based Sorrento, which is developing antibody treatments against SARS-CoV-2, said preclinical data showed its COVI-GUARD and COVI-AMG antibodies demonstrated potent neutralizing activities against the virus that caused COVID-19. COVI-GUARD is codenamed STI-1499 and COVI-AMG is codenamed STI-2020. In pre-clinical cell-based assays, both the antibodies showed 100% in vitro neutralization of SARS-CoV-2 at concentrations of 6 microgram/ml and 78 ng/ml, respectively, the company said. The observed neutralization activity protected against both SARS-CoV and the highly contagious Spike D614G … Full story available on Benzinga.com

Benzinga | September 29, 2020

Why Sorrento Therapeutics Is Trading Higher Today

Sorrento Therapeutics, Inc . (NASDAQ: SRNE ) shares are trading higher on Monday after the company released results of its Phase 1B trial of resiniferatoxin in reduction of osteoarthritis knee pain. Sorrento Therapeutics is a biotechnology company … Full story available on Benzinga.com

Benzinga | September 28, 2020

FDA Clearance Means It's Go Time for Sorrento Therapeutics

It's a great time to be long SRNE stock as the company's ambitious Covid-19 treatment clinical trials take a giant step forward.

InvestorPlace | September 25, 2020

Sorrento sees positive results in Phase 1B trial of Resiniferatoxin Epidural in cancer patients with reported intractable pain

Seventeen subjects with advanced cancer pain received epidural RTX (0.4 to 25 mcg). No dose limiting toxicities were reported, and a majority of patients reported meaningful pain reduction of 30% or more vs. baseline.Sorrento (SRNE) expects to immediately submit to the FDA a request to proceed with a Phase 3...

Seeking Alpha | September 22, 2020

Read More 'SRNE' Stories Here

SRNE Price Returns

1-mo -15.74%
3-mo 5.38%
6-mo 219.84%
1-year 444.37%
3-year 193.57%
5-year 2.62%
YTD 143.20%
2019 40.83%
2018 -36.84%
2017 -22.45%
2016 -43.74%
2015 -13.51%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7143 seconds.